Valeant CEO Joseph Papa speaks about comeback plan with stock at 17-year low

Valeant's chief executive officer, Joseph Papa, spoke with CNBC about the state of drug pricing, a possible sale of the company's assets in an effort to reduce debt and how he plans to appease investors' fears with the stock at a 17-year low.

Year to date, shares of the pharmaceutical company have plunged 87 percent compared with a 10 percent gain for the S&P 500 index. Papa took over as CEO in April 2016.

Only PRO subscribers have access to the full interview, which was originally broadcast on "Closing Bell."